Chronic Lymphocytic Leukemia Coverage from Every Angle

Recent News

ASH 2019: Acalabrutinib Combination Therapy for Previously Untreated CLL
Study Reports Early-Stage Impairment of Neutrophil Activity With Ibrutinib for CLL
FDA Approves Indication for Acalabrutinib in Chronic Lymphocytic Leukemia
Prognostic Value of Residual Lymphadenopathy After Chemoimmunotherapy for CLL
Weight Gain With Ibrutinib Treatment in Patients With CLL
Aging and Stereotypic B-Cell Receptors Associated With CLL
Using Minimal Residual Disease Detection to Monitor Outcomes in CLL Treatment
First-in-Human Study of CD200 Blockade With Samalizumab in CLL
Update on Resistance to Targeted Therapies in CLL
STIM1 Targeting as a Novel Therapy for Patients With CLL
SOHO 2019: Novel Reversible BTK Inhibitor Therapy for Chronic Lymphocytic Leukemia
SOHO 2019: ‘More Questions Than Answers’ in CLL Therapy
Case of Cranial Aspergillosis in a Patient Receiving Ibrutinib for CLL
Extended Ibrutinib Treatment in RESONATE CLL Trial
ALPINE Trial: Bruton’s Tyrosine Kinase Inhibitor in Resistant CLL
Managing Toxicity With Duvelisib in CLL: Dose Reductions or Interruptions
Venetoclax Plus Obinutuzumab in Patients With Untreated CLL
Epigenetic Diversity in CLL
Acalabrutinib Plus Obinutuzumab in Resistant CLL: 3-Year Follow-up
Final Results of COMPLEMENT 1 Trial: Ofatumumab and Chlorambucil in Untreated CLL
Potential Prognostic Markers in CLL: NOTCH1 Pathway Mutations
Atrial Fibrillation After Treatment With Ibrutinib in Patients With CLL
Treatment of Resistant CLL With Acalabrutinib
Acalabrutinib Granted Breakthrough Therapy Designation in CLL
CLL14 Trial: Paired With Obinutuzumab, Venetoclax Versus Chlorambucil in CLL
Acalabrutinib in Relapsed or Refractory CLL
CLL12 Trial: Ibrutinib Improves Outcomes in Early-Stage CLL
RESONATE2 Update on First-Line Ibrutinib in Older Patients With CLL/SLL
Secondary Cancers and BTK Inhibitors for CLL
Umbralisib in Kinase Inhibitor–Intolerant CLL
Method for Selecting Potential Ibrutinib-Based Combinations in CLL
CD19-Directed Immunotherapy for Relapsed or Refractory CLL
FDA Approves Rituximab Biosimilar for CLL
Obesity and Chemoimmunotherapy Outcomes for Patients With CLL
FDA Approves Venetoclax Plus Obinutuzumab as First-Line Treatment for CLL/SLL
Concurrent CLL, Kaposi Sarcoma, and Angiosarcoma
Does Ibrutinib Pose Cardiac or Pulmonary Risk in Patients With CLL?
Does Size of Extracellular Vesicles Impact Immunotherapy for CLL?
EHA24 Congress: ASCEND Trial of Acalabrutinib Monotherapy in Resistant CLL

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.